Technology Trumps Lymphoma … Again

Children undergoing treatment for lymphoma have to deal with so much that often, what’s sacrificed is not just the kind of social interaction every child deserves, but also schoolwork and the chance to keep up with their peers.



According to Dr. Aziza Shad, chief of Division of Pediatric Hematology/Oncology at Georgetown University Medical Center, these kids can miss as much as three years of schoolwork during treatment.



A regional chapter of the Leukemia and Lymphoma Society has taken a fantastic step to overcome that problem for kids undergoing treatment for lymphoma at Georgetown University Med Center in the Nation’s capital. The Society has donated to the hospital six laptops, all of which feature built-in Web cams so these kids can not only keep up with their schoolwork, they can also socialize with their friends and take part in lesson plans—in short, stay connected.



Six nicely equipped laptops is all it takes to help keep these kids feeling like they’re part of the everyday life of their peers. Can you imagine what this means for them? And can you imagine how little it required on the part of the donors?


More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap